Advanced Medical Solutions Group Plc · LSE:AMS
Advanced Medical Solutions — FY2021 Earnings Presentation
19 slides from Advanced Medical Solutions's earnings presentation, March 2022
Slide 1: Advanced Medical Solutions Group plc
Advanced Medical Solutions Group pic
Slide 2: Financial Highlights
Financial Highlights Strong revenue growth, profit and cash generation + Full year revenue up 29%* to £108.6 million (2020: £86.8 million), as elective surgery and wound treatment volumes continue to rebuild towards pre-pandemic levels + Adjusted profit before tax up 92% to £25.6 million (2020: £13.
Slide 3: Operational Highlights
Operational Highlights Regulatory and clinical progress as investment continues in next-generation products SEAL-G® and SEAL-G® MIST clinical study continues to progress well with approximately 25% of patients now recruited. Clinical results on track to be released in H2 2022 to support full commerc
Slide 4: Product Progress: LiquiBand®
Product Progress: LiquiBand® LiquiBand® US + Recovery of elective surgery volumes, LiquiBand® Rapid roll-out, inventory replenishment and successful re-focusing of the marketing strategy driving significant growth and record end sales volumes * Later than planned but LiquiBand® XL 510(k) approval an
Slide 5: Product Progress: LiquiBand Fix8®
Product Progress: LiquiBand Fix8® LiquiBand Fix8® US approval process is progressing well * Recruitment of US clinical trial complete * 12-month follow-up and interim report on track for H2 2022 + PMA submission anticipated in H2 2022 LiquiBand Fix8® ROW + Steady recovery in demand reflects non-esse
Slide 6: Product Progress: SEAL-G® and SEAL-G® MIST
Product Progress: SEAL-G® and SEAL-G® MIST Regulatory * CE Mark approval for SEAL-G® MIST (laparoscopic) and CE mark extension for SEAL-G® (open) granted in 2021 Clinical study + First human clinical study progressing well with about 25% of patients recruited YD + Additional five trial sites now rec
Slide 7: Product Progress: Biosurgical Devices
Product Progress: Biosurgical Devices Collagens + Work is progressing with MDR approval process for antibiotic loaded collagens : + Dental and orthopaedic procedures slower to recover following COVID-19 restrictions bY + 510(k) submission planned in 2023 for dental collagen - the first application o
Slide 8: Product Progress: Infection Management Woundcare
Product Progress: Infection Management Woundcare + Shipments of differentiated Silver alginate range re-started in H2 2021 following re-negotiation of contract with key customer; AMS already gaining new business through direct marketing of this product into new markets + Antimicrobial US claim appro
Slide 9: Product Progress: Woundcare Exudate Management
Product Progress: Woundcare Exudate Management + Integration of Raleigh Coatings continues to progress well with the in-sourcing of woundcare manufacturing processes expected to come on stream and save costs in 2022 + New distributors appointed for ActivHeal® in APAC and Gulf States + Woundcare dist
Slide 10: Acquisition of AFS Medical GmbH
Acquisition of AFS Medical GmbH Expands AMS’ direct sales presence and expertise + Agreement signed to acquire AFS Medical GmbH (““AFS”) + Aspecialist distributor of minimally invasive surgical devices, headquartered in Vienna with a Direct Sales team in Austria + AFS has already been successful in
Slide 11: Financial Summary
Financial Summary
Slide 12: Growth rate shown at constant currency
• • • • • • *Growth rate shown at constant currency 12
Slide 13: FY 2021 Results: Surgical Revenue
B FY 2021 Results: Surgical Revenue Revenue up 29% to £64.6 million (2020: £50.2 million) Advanced Closure + LiquiBand® revenue up 46% to £33.1 million (2020: £22.8 million) * Growth driven by increased end-user demand, LiquiBand® Rapid roll out, refocusing of US marketing and some re- stocking by o
Slide 14: FY 2021 Results: Woundcare Revenue
FY 2021 Results: Woundcare Revenue Infection Management Exudate Management 20 25 Revenue up 20% to £44.0 million 2B (2020: £36.6 million) 15 15 Infection Management 10 * Revenue down 1% to 15.1 million (2020: £15.3 million) 5 10 + New silver alginate contract drove growth in H2, but lack 5 of orders
Slide 15: FY 2021 Operating Margins
FY 2021 Operating Margins Surgical —£M Surgical Business Unit + Increased product volumes generating greater 31.4% 60.0 30.0% operational leverage and significant improvement 400 181% 20.0% in margins 20.0 10.0% * Strong recovery in US LiquiBand® sales providing 0.0 0.0% “ye . 7 2020 2021 a positive
Slide 16: Balance Sheet to Dec 2021
Balance Sheet to Dec 2021 Dec 2020 Dec 2021 Property, Plant and Equipment and other Fixed Assets Goodwill and Acquired Intangibles Fixed Assets Stock Debtors Cash Current Assets Creditors Lease liabilities Borrowings Losses on FX contracts Tax Liabilities Net Assets 202.3 212.7 Annual capex set to i
Slide 17: Summary and Outlook
Summary and Outlook
Slide 18: Summary and Outlook
Summary and Outlook Positioned for further growth with a promising pipeline of next-generation products AMS' core businesses recovered strongly in 2021 as markets recovered from the impact of COVID-19 Good progress has been made in expanding our geographic footprint with new distributors appointed a
Slide 19: Advanced Medical Solutions plc
Advanced Medical Solutions plc Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire W7 3RT, UK Chris Meredith (Chief Executive Officer) Eddie Johnson (Chief Financial Officer) Michael King (Investor Relations) corporate@admedsol.com +44 (0)1606 863500 www.admedsol.com jedical So
Advanced Medical Solutions Group — FY2021 Earnings Presentation on 6ix